

Cutaneous lymphomas: update of laboratory diagnosis.

M. Alaibac, E. Tonin, A. Peserico, C. Veller-Fornasa

S U M M A R Y

The term primary cutaneous lymphomas designates a heterogeneous group of lymphoproliferative disorders arising from skin-homing T and B cells. The European Organization for Research and Treatment of Cancer (EORTC) classification for primary cutaneous lymphomas recognizes a limited number of cutaneous T-cell lymphomas and cutaneous B-cell lymphomas and provides a working classification for cutaneous lymphomas. Herein, the diagnostic procedures for the diagnoses of cutaneous lymphomas are discussed. Recent developments regarding immunophenotyping and immunogenotyping of cutaneous T-cell lymphomas and cutaneous B-cell lymphomas recognized in the EORTC classification are presented.

K E Y W O R D S

cutaneous lymphomas, T cell, B cell, classification, immunophenotyping, immunogenotyping, review

The term primary cutaneous lymphomas designates a heterogeneous group of lymphoproliferative disorders arising from skin-homing T and B cells which present in the skin with no evidence of extracutaneous disease at the time of diagnosis and six months thereafter (1-3). They are after the group of gastrointestinal lymphomas the second most common group of extranodal non-Hodgkin lymphomas with an annual incidence of 1-1.5/100,000.

Classification.

The European Organization for Research and Treatment of Cancer Classification (EORTC) uses a combination of clinical, histological, immunophenotypic, and molecular biological characteristics and provides a

working classification for cutaneous lymphomas (Table I) (4). The diagnosis of cutaneous lymphomas is made by recognizing the clinical manifestations and is supported by laboratory tests. Immunophenotyping (immunologic analysis of cellular antigen expression) and immunogenotyping (molecular biology analysis of antigen receptor genes) support the conventional clinical and histopathologic analyses.

Immunophenotyping of cutaneous lymphomas.

The distinction between cutaneous lymphomas and non-lymphoid tumors of the skin is a common problem. The most useful immunohistochemical marker in

this situation is the CD45 antibody reacting with all the known isotypes of the CD45 family, also called the leukocyte common antigen family (LCA family). The antibody labels the cell membrane of almost all leukocytes and is absent on non-haematopoietic cells (5).

Mycosis fungoides is a neoplasm of T helper lymphocytes expressing the CD4 molecule and the pan-T-cell antigens CD2 and CD3 (1). They generally express the T-cell receptor molecules that consist of α and β chains (TCR $\alpha\beta$) (6). Partial or complete loss of the T cell associated antigens CD5 and CD7 can sometimes be observed particularly among the intraepidermal T cells and in the late stage of the disease (7, 8). This aberrant phenotype is considered circumstantial evidence of a neoplastic proliferation of T-cells. A small percentage of cases express CD8 rather than CD4. Benign reactive cutaneous diseases such as chronic eczema and psoriasis show the same pattern as that in early stage of mycosis fungoides (9). However cutaneous infiltrations in early mycosis fungoides contain significantly more CD4+ cells than those of benign lymphoid disorders. The CD4/CD8 ratio has been shown to be 4/1 in benign lymphoid infiltrates, 7/1 in the patch stage of mycosis fungoides, 14/1 in the plaque stage of MF and 24/1 in the tumor stage (9).

Patients may have atypical lymphocytes with cerebriform nuclei (Sezary cells) in the peripheral blood. The current practice is to use a criterion of at least 20% cerebriform lymphocytes to define Sezary syndrome (10). Immunophenotypic studies of the peripheral blood may show expansion of a CD4+CD7- population reflective of circulating atypical lymphocytes (10).

Primary cutaneous large T-cell CD30+ lymphoma is the most common form on non-MF primary CTCL. The spectrum of primary cutaneous CD30+ lymphoproliferative disorders includes lymphomatoid papulosis, primary cutaneous large T-cell CD30+ lymphoma and intermediate forms (11). Lymphomatoid papulosis is characterized by scattered CD30+ blast cells whereas primary cutaneous large T-cell CD30+ lymphomas demonstrate diffuse infiltrates of large anaplastic CD30+ T cells (11, 12). The CD30 molecule is expressed on the majority (>75%) of neoplastic cells. Most cases express the CD4+CD30+ phenotype with variable loss of pan-T cell antigens (CD2, CD3, CD5, or CD7). A small minority of cases is CD8+CD30+(12).

Primary cutaneous large T-cell CD30- lymphomas are characterized by minimal or absent CD30 expression (11, 13). Tumor cells express a phenotype of the CD4+ lymphocyte subset. Occasional cases express CD8.

Primary cutaneous pleomorphic small/medium-sized T-cell lymphomas are characterized by deep and

Table 1. EORTC classification for primary cutaneous lymphomas.

<i>Cutaneous T-cell lymphoma (CTCL)</i>
Indolent clinical behaviour
Mycosis fungoides Mycosis fungoides variants: follicular MF and pagetoid reticulosis CTCL, large cell, CD30-positive (anaplastic, immunoblastic and large pleomorphic) Lymphomatoid papulosis
Aggressive clinical behaviour
Sezary syndrome CTCL, large cell, CD30-negative (immunoblastic and large pleomorphic)
Provisional entities
CTCL, pleomorphic, small/medium-sized Subcutaneous panniculitis-like T-cell lymphoma
<i>Cutaneous B-cell lymphoma (CBCL)</i>
Indolent clinical behaviour
Primary cutaneous immunocytoma/marginal zone B-cell lymphoma Primary cutaneous follicle center cell lymphoma
Intermediate clinical behaviour
Primary cutaneous large B-cell lymphoma of the leg
Provisional entities
Primary cutaneous plasmacytoma Intravascular large B-cell lymphoma

diffuse infiltrates composed of small-to-medium sized atypical lymphoid cells expressing the CD4 molecule (11, 14). CD8+ cutaneous pleomorphic lymphomas are rarely observed. A small minority expresses the $\gamma\delta$ TCR and is characterized by an aggressive behavior. The loss of one or more pan-T antigens (CD2, CD3, CD5, or CD7) can be observed.

Primary cutaneous B-cell lymphomas are characterized by a dense infiltrate of tumor cells expressing B-cell surface antigens, notably CD19, CD20, CD22 and CD79a (15, 16). Neoplastic cells may be Ig+ or Ig-. Ig+ B-cell lymphomas are monoclonal, ie, all tumor cells express the same Ig light chain, either κ or λ (15). This phenomenon is denominated light chain restriction. Reactive polyclonal B-cell infiltrates are composed of a mixture of κ and λ cells, typically with approximately

2:1 κ predominance. Therefore, the presence of light chain restriction is consistent with the presence of a CBCL.

Immunogenotyping of cutaneous lymphomas.

The use of molecular biologic techniques has improved our ability to diagnose lymphocytic infiltrate of the skin and provided additional diagnostic parameters to complement clinical, histologic and immunophenotypic analysis. Molecular characterization involves the identification of a monoclonal population of lymphocytes which is based upon the detection of specific rearrangements in the genes coding for antigen receptor in B-cells (Ig) and T-cells (the T-cell antigen receptor) (16,17). Southern blot analysis of genes coding for Ig or for T-cell receptor was the method used in initial studies, which showed evidence for the monoclonal nature of both cutaneous T cell lymphoma (CTCL) and cutaneous B cell lymphoma (CBCL). More recently, Southern blot hybridization has been challenged by the polymerase chain reaction (PCR) for the routine analysis of clonality (18).

Studies of clonality by means of PCR in patients with MF revealed clonal patterns in tumorous lesions, in erythrodermal stages, and in most infiltrated plaques,

whereas a dominant clone was not found in 40% of non-infiltrated patch lesions (19-21).

The immunogenotyping studies of primary cutaneous CD30+ lymphoproliferative disorders have shown the clonal T-cell nature of these disorders (11). In particular the TCR gene rearrangement analysis of lymphomatoid papulosis, which is characterized by a clinically benign course, has shown evidence of monoclonality in the cases analyzed (22). A similar monoclonal pattern has been observed in the other subtypes of CTCL, notably primary cutaneous large T-cell CD30-lymphomas and primary cutaneous pleomorphic small/medium-sized T-cell lymphomas (11).

Immunogenotyping studies in CBCL have shown in most cases a monoclonal process; however, they differ from nodal lymphoma in that they rarely show the t(14,18) translocation (23-25).

Since polyclonal patterns of TCR and immunoglobulin rearrangements were found in most benign inflammatory dermatosis one might argue that the molecular demonstration of clonal proliferation of lymphocytes provides strong evidence for malignancy. However recent studies have shown monoclonality in patients with benign cutaneous lymphoid infiltrate (18). These results indicate that monoclonality is not conclusive evidence for malignancy and that results from clonality studies should be interpreted in the context of histopathological, immunohistochemical and clinical data.

REFERENCES

1. Damandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. *Blood* 1996; 88:2385-409.
2. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphomas: review and current concepts. *J Clin Oncol* 2000; 18:2908-25.
3. Pandolfino T, Siegel RS, Kuzel TM, Rosen S, Guitart J. Primary cutaneous B-cell lymphomas: review and current concepts. *J Clin Oncol* 2000; 18:2152-68.
4. Willemze R, Meijer CJ. EORTC classification for primary cutaneous lymphomas: the best guide to good clinical management. *Am J Dermatopathol* 1999; 21:265-73.
5. Swinzer R. Cluster report: CD45/CD45R. In: Knapp W et al., eds. *Leukocyte typing IV. White cell differentiation antigens*. Oxford-New York- Tokio: Oxford University Press, 1989:628-34.
6. Berman R, Faclieru D, Sahar D, Sander CA, Kerner H, Ben-Aryeh Y et al. Immunophenotyping and T-cell receptor gene rearrangement analysis as an adjunct to the histopathologic diagnosis of mycosis fungoides. *J Am Acad Dermatol* 1988; 39:554-9.
7. Michie SA, Abel EA, Hoppe RT, Warnke RA, Wood GS. Discordant expression of antigens between intraepidermal and intradermal T cells in mycosis fungoides. *Am J Pathol* 1990; 137:1447-51.
8. Preesman AH, Toonstra J, van der Putte SC, van Vloten WA. Immunophenotyping on simultaneously occurring plaques and tumours in mycosis fungoides and Sezary syndrome. *Br J Dermatol* 1993; 129:660-6.
9. Nagatani T, Kim S, Baba N, Miyamoto H, Shimoyama M et al. Phenotypic heterogeneity of lymphoma of the skin. *J Dermatol* 1989; 16:443-52.
10. Harman CB, Witzig TE, Katzmann JA, Pittelkow MR. Detection of circulating T cells with CD4+CD7-

- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. *J Am Acad Dermatol* 1996; 35:404-10.
11. Gilliam AC, Wood GS. Primary cutaneous lymphomas other than mycosis fungoides. *Semin Oncol* 1999; 26:290-306.
 12. Parks JD, Synovec MS, Masih AS, Braddock SW, Nakamine H, Sanger WG et al. Immunophenotypic and genotypic characterization of lymphomatoid papulosis. *J Am Acad Dermatol* 1992; 26: 968-75.
 13. Willemze R, Beljiaards RC, Meijer CJLM. Classification of primary cutaneous large cell lymphomas. *Dermatol Clin* 1994; 12:361-73.
 14. Bejjiaards RC, Meijer CJ, Van der Putte SC, Hollema H, Geerts ML, Bezemer PD et al. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. *J Pathol* 1994; 172:53-60.
 15. Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases. *Cancer* 1991; 67:2311-26.
 16. Yang B, Tubbs RR, Finn W, Carlson A, Pettay J, Hsi ED. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. *Am J Surg Pathol* 2000; 24:694-702.
 17. Weinberg JM, Rook AH, Lessin SR. Molecular diagnosis of lymphocytic infiltrates of the skin. *Arch Dermatol* 1993; 129:1491-1500.
 18. Bachelez H. The clinical use of molecular analysis of clonality in cutaneous lymphocytic infiltrates. *Arch Dermatol* 1999; 135:200-2.
 19. Bottaro M, Berti E, Biondi A, Migone N, Crosti L. Heteroduplex analysis of T-cell receptor gamma gene rearrangements for diagnosis and monitoring of cutaneous T-cell lymphomas. *Blood* 1994; 83:3271-8.
 20. Yu RC, Alaibac M. A rapid PCR-based technique for detecting clonal T-cell receptor gene rearrangements in cutaneous T-cell lymphomas of both the alpha beta and gamma delta varieties. *Diagn Mol Pathol* 1996; 5:121-6.
 21. Bakels V, van Oostveen JW, van der Putte SC, Meijer CJ, Willemze R. Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas. *Am J Pathol* 1997; 150:1941-9.
 22. Wood GS, Crooks CE, Uler AZ. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. *J Invest Dermatol* 1995; 105:51-5.
 23. Neri A, Fracchiolla NS, Roscetti E, Garatti S, Trecca D, Boletini A et al. Molecular analysis of cutaneous B- and T-cell lymphomas. *Blood* 1995; 86:3160-72.
 24. Saxena A, Angel S, Geldenhuys L, Hull Pr. A combination of abnormal immunoarchitecture and reproducible clonal bands identifies the biologic nature of cutaneous B-cell infiltrates. *Am J Clin Pathol* 1999; 112:495-512.
 25. Gronbaek K, Moller PH, Nedergaard T, Thomsen K, Baadsgaard O, Hou-Jensen K et al. Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. *Br J Dermatol* 2000; 142:913-23.

A U T H O R S ' A D D R E S S E S *Mauro Alaibac, MD, PhD, Clinica Dermatologica, Università di Padova, Via C. Battisti 206, 35100, Padova, Italy*
Elena Tonin, MD, resident, same address
Andrea Peserico, MD, professor of dermatology, same address
Cleto Veller-Fornasa, MD, professor of dermatology, same address